

# Kamaraj Karunanithi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4649868/publications.pdf>

Version: 2024-02-01

5  
papers

344  
citations

1684188

5  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

654  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 57-73.	10.7	245
2	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e616-e629.	4.6	42
3	Copy number evolution and its relationship with patient outcome—analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , 2021, 35, 2043-2053.	7.2	23
4	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003454.	8.4	18
5	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	3.5	16